CDC advises updated COVID vaccine for everyone over 6 months of age
Jun 28, 2024
Americans 65 and older account for two-thirds of COVID hospitalizations and 82% of in-hospital deaths, yet only about 40% of Americans in that age group were immunized with the COVID vaccines that were...
FDA approves Capvaxive pneumococcal 21-valent conjugate vaccine
Jun 21, 2024
Merck says the vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults aged 50 or more years.
All participants exceeded twofold increase in spike-specific IgG, with a geometric mean fold risk of 19.5 on day 57.
mRNA vaccines effectively prevent SARS-CoV-2 in adults in real-world setting
Jul 01, 2021
For those with SARS-CoV-2 infection, vaccinated participants had a lower mean viral load, risk of febrile symptoms and illness duration.
Protection against SARS-CoV-2 wanes months after BNT162b2 vaccination
Oct 08, 2021
Declines were seen in humoral responses and effectiveness against SARS-CoV-2 infection within several months after the second dose of the Pfizer-BioNTech vaccine, also known as Comirnaty.
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
COVID-19 vaccination does not negatively impact fertility
Aug 24, 2022
The findings were seen for women undergoing in vitro fertilization-fresh embryo transfer cycle.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Preexisting conditions seen in all patients with tachycardia after COVID-19 vaccine
Jan 10, 2024
Reduced heart rate variability was observed in patients with postvaccination postural orthostatic tachycardia syndrome.
Bivalent mRNA-1273.214 elicits better response against omicron
Sep 27, 2022
A booster dose of mRNA-1273.214 elicits more neutralizing antibodies against omicron compared with mRNA-1273, the original Moderna vaccine, with no new safety concerns.